Westley Croup Score
- Consider croup (laryngotracheobronchitis) in patients aged 6 months to 6 years with acute-onset syndrome of stridor, barking cough, hoarseness, and respiratory distress, sometimes concurrently with URI symptoms.
- Croup is a clinical diagnosis based on history and physical exam. Severity of croup can be quantified via the Westley Croup Score, though, clinically it is not used to guide therapy. Instead, it is used to measure a patient’s response to therapy.
- Researchers have attempted to separate this entity from “spasmodic” (i.e., recurrent, short-lived) croup, which may be due to allergic reaction of viral antigens.
- Presentation and pathology may be the same, which makes response to treatment difficult to determine. As a result, many authorities consider these entities part of the same disease spectrum
- This score is traditionally used for clinical research purposes in order to track patient response over time to treatment.
- Has been used with moderate reliability to assess for post-extubation upper airway obstruction.
- The original score (Westley 1978) was derived to objectively measure a clinical state in order to allow comparisons over time in response to treatment.
- Developed to compare the response of nebulized racemic EPINEPHrine versus saline, not to derive a prognostic scoring system.
- The range of values for each of the five items was arbitrary and each was weighted based on the clinical implications of the most critical form of each sign.
- Follow-up studies demonstrated construct validity (Klassen 1999), with multiple studies showing high inter-rater reliability (Klassen 1999, Super 1989).
- Most commonly used scoring system for croup.
- Designed to measure severity for research settings, but often applied to prognosticate. May be useful in determining treatment efficacy and patient disposition.
- Has fair inter-rater reliability in clinical users (though better in research studies).
- Change in score correlates well with patient disposition and global assessment as rated by both parents and ED physicians.
- Continues to be used in studies for treatment of croup since its validity and reliability among users were demonstrated.
Please fill out required fields.
About the Creator
Terry Klassen, MD, is the CEO and Scientific Director for the Children’s Hospital Research Institute of Manitoba. He is also head of the Department of Pediatrics and Child Health and scientific director of the George and Fay Yee Centre for Healthcare Innovation at the University of Manitoba. Dr. Klassen co-founded StaR Child Health to improve child-focused randomized control trial design, implementation and publication.
To view Dr. Terry Klassen's publications, visit PubMed